Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Maternity
  4. Back
  5. Medical conditions in pregnancy - diabetes
  6. Diabetes, continuous subcutaneous insulin infusion (CSII) in labour: Protocol for patient self management (521)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Diabetes, continuous subcutaneous insulin infusion (CSII) in labour: Protocol for patient self management (521)

Warning

Please report any inaccuracies or issues with this guideline using our online form

General notes

This protocol is for women who choose to continue to use their insulin pump (CSII) in labour.

Women following this guideline must be aware that clinical staff will NOT adjust settings on pump and that they will not advise of setting changes outwith those discussed in this guideline.

Women must be aware that wishes to continue pump will be taken seriously but there is a need to be flexible with clinical recommendations.

IF AT ANY POINT THE WOMAN BECOMES UNABLE TO MANAGE THE DEVICE THEN THEY SHOULD BE SWITCHED TO INTRAVENOUS INSULIN AND THE PUMP STOPPED. IT IS NOT APPROPRIATE FOR MIDWIFERY STAFF OR BIRTH PARTNERS TO ADJUST THE INSULIN PUMP.

Caesarean Section

There is a risk that diathermy will interfere with the insulin pump settings. 

For women undergoing Caesarean section the pump should be disconnected from the infusion set prior to the procedure, and IV insulin infusion as per guideline should be established. The infusion set can be left in situ.

Following delivery the pump can be re-connected to the infusion set. Insulin settings after delivery are 50-75% of the pre-pregnancy doses (see below) 

Equipment

All women should have

  • 2 x Spare set of batteries
  • 2 x reservoirs
  • 5 x infusion sets including lines (and inserter device)
  • Back-up insulin pens (long and short acting insulin)

At onset of labour (0-4cm) – NB: many women will be at home

  • Woman should ensure:
    • New batteries inserted into pump
    • Fill a new reservoir with insulin
    • Put in a complete new infusion set (including line)
    • Locate the infusion site below rib cage and towards back so that it will not interfere with emergency intervention
  • Continue current basal rates and bolus ratios.
  • Pregnant woman or midwife should check capillary blood glucose (CBG) 2 hourly or sooner if symptomatic of hypoglycemia
  • Pregnant woman should treat hypoglycaemia as she would if not in labour
  • If more than 2 hypoglycemic events during the initial stage of labour, then woman should reduce all basal rates by 50%
  • If CBG > 10 mmol/l then check ketones and give a correction dose as per sensitivity (see guidance below)

Active labour (4cm-delivery)

  • IV access should be obtained in case of need for IV insulin therapy or treatment of severe hypoglycemia
  • Basal insulin should continue at current rates
  • Women are not usually advised to eat/drink during this stage but if they do, then bolus insulin ratio should be given at the same ratios as before labour.
  • Blood glucose monitoring should be taken hourly by pregnant woman/clinical team and recorded by clinical team (using the insulin sliding scale in labour chart)

  • If CBG < 4 mmol/l, then treat the hypoglycaemia as normal (may require IV glucose if strictly NBM)
  • If CBG < 4 mmol/l on more than one occasion, then reduce basal rate further by 50%
  • If CBG >10 mmol/l
    • Check for ketones
    • If ketones positive then start IV insulin sliding scale with fluids immediately, with insulin pump continuing in background
    • If ketone negative give correction dose as per below sensitivity and recheck in 1 hour
    • If CBG not falling repeat this step and recheck CBG after 1 hour
    • If CBG rising despite correction dose or not coming down after 2 correction doses then start IV insulin infusion (continue pump in background and perform set change)

Immediately (within 30 minutes) after delivery:

  • Immediately following delivery of placenta, the basal rates on pump should be set to 50-75% of pre-pregnancy rates and bolus ratios should also be administered at 50-75% of prepregnancy doses. These should be prescribed on attached sheet and discussed with the woman.
  • If the pre-pregnancy rates are not known, the diabetes team should advise what basal rates should be set to and bolus ratio should start at 1 unit for 20g carbohydrate.
  • Women on CSII are usually very comfortable managing their diabetes and should not be discouraged from adjusting their own settings Review by diabetes team within 24-48 hours of delivery

IF AT ANY POINT THE WOMAN BECOMES UNABLE TO MANAGE THE DEVICE THEN A SWITCH TO INTRAVENOUS INSULIN SHOULD TAKE PLACE AND THE PUMP STOPPED.

IF AT ANY POINT THE WOMAN BECOMES UNABLE TO MANAGE THE DEVICE THEN A SWITCH TOINTRAVENOUS INSULIN SHOULD TAKE PLACE AND THE PUMP STOPPED.

List not exhaustive but may include:

  • Pregnant woman too distressed or uncomfortable to manage the pump
  • Complications with clinical staff feeling that the more familiar IV insulin therapy be commenced instead – please discuss with woman
  • Erratic blood sugars with multiple adjustments required during labour
  • Requirement for Caesarean Section

Insulin prescription as suggested by Diabetes team

Patient

CHI

Diabetes type

PRE-LABOUR/EARLY LABOUR

basal rates:

bolus ratio:

Correction e.g. 1 unit will correct by 3 mmol/l:

ACTIVE LABOUR (4cm dilatation-delivery)

Basal rates:    

 bolus ratio:

Correction doses e.g. 1 unit will correct by how many mmol/l:

FIRST 24-48 HOURS POST-DELIVERY OF PLACENTA:

Basal rates:       

 bolus ratio:

Correction doses e.g. 1 unit will correct by how many mmol/l:

Back-up Insulin pens- insulin type and dose. 

Diabetes StR/Consultant should review within 24-48 hours of delivery to advise on further dose adjustment.

Editorial Information

Last reviewed: 26/04/2018

Next review date: 01/03/2022

Author(s): David Carty.

Version: 2

Approved By: Obstetrics Clinical Governance Group

Document Id: 521